Atlas Capital Advisors Inc. Has $214,000 Stock Holdings in Grifols, S.A. (NASDAQ:GRFS)

Key Points

• Atlas Capital Advisors Inc. significantly increased its stake in Grifols, S.A. by 3,948.1%, acquiring a total of 30,118 shares valued at $214,000 as of the latest SEC filing.
• Grifols recently declared a dividend of $0.1404 per share that will be paid to investors on August 20th, with an ex-dividend date of August 12th.
• Analysts have mixed ratings on Grifols, with an average rating of "Buy" and a consensus price target of $10.30, reflecting a recent upgrade from "buy" to "strong-buy" by Wall Street Zen.

Atlas Capital Advisors Inc. lifted its holdings in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 3,948.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 30,118 shares of the biotechnology company's stock after acquiring an additional 29,374 shares during the quarter. Atlas Capital Advisors Inc.'s holdings in Grifols were worth $214,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of GRFS. Capital World Investors boosted its stake in Grifols by 0.7% in the fourth quarter. Capital World Investors now owns 21,134,230 shares of the biotechnology company's stock valued at $157,239,000 after acquiring an additional 154,358 shares during the period. Black Creek Investment Management Inc. boosted its stake in Grifols by 1.3% in the fourth quarter. Black Creek Investment Management Inc. now owns 11,251,960 shares of the biotechnology company's stock valued at $83,715,000 after acquiring an additional 141,615 shares during the period. Soleus Capital Management L.P. boosted its stake in Grifols by 46.1% in the fourth quarter. Soleus Capital Management L.P. now owns 6,605,425 shares of the biotechnology company's stock valued at $49,144,000 after acquiring an additional 2,083,722 shares during the period. Janus Henderson Group PLC boosted its stake in Grifols by 11.9% in the fourth quarter. Janus Henderson Group PLC now owns 3,045,260 shares of the biotechnology company's stock valued at $22,642,000 after acquiring an additional 324,869 shares during the period. Finally, New York State Common Retirement Fund boosted its stake in Grifols by 50.5% in the first quarter. New York State Common Retirement Fund now owns 2,452,728 shares of the biotechnology company's stock valued at $17,439,000 after acquiring an additional 823,456 shares during the period.

Grifols Trading Down 0.3%

Shares of NASDAQ GRFS traded down $0.04 during midday trading on Friday, reaching $10.71. 386,581 shares of the stock were exchanged, compared to its average volume of 989,144. The business has a 50-day simple moving average of $9.61 and a two-hundred day simple moving average of $8.23. The company has a market capitalization of $7.36 billion, a price-to-earnings ratio of 9.15, a P/E/G ratio of 0.36 and a beta of 0.56. Grifols, S.A. has a 12 month low of $6.19 and a 12 month high of $11.14. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.64 and a quick ratio of 0.95.

Grifols Dividend Announcement

The firm also recently declared a -- dividend, which will be paid on Wednesday, August 20th. Shareholders of record on Tuesday, August 12th will be paid a $0.1404 dividend. The ex-dividend date is Tuesday, August 12th. Grifols's payout ratio is presently 11.97%.

Wall Street Analysts Forecast Growth

GRFS has been the subject of several analyst reports. JPMorgan Chase & Co. boosted their price objective on Grifols from $7.60 to $10.30 and gave the stock a "neutral" rating in a research report on Tuesday, June 17th. Zacks Research upgraded Grifols to a "hold" rating in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Grifols in a report on Tuesday, August 5th. Finally, Wall Street Zen raised Grifols from a "buy" rating to a "strong-buy" rating in a report on Monday, July 7th. Three analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $10.30.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.